Shares of eyecare company Bausch + Lomb (NYSE:BLCO)
fell 3.1% in the morning session after the company reported mixed second-quarter 2025 financial results where a decline in profitability overshadowed revenue growth and a raised forecast. While the company's revenue increased by 5% year-over-year to $1.28 billion, beating analyst expectations, its underlying earnings disappointed investors. The growth was primarily driven by its Vision Care segment, and the company also raised its full-year revenue guidance. However, Bausch + Lomb posted a GAAP net loss of $62 million for the quarter. Furthermore, its adjusted net income fell to $25 million from $45 million in the same period a year earlier. This drop in profitability, attributed to higher operational costs and the recall of its enVista Intraocular Lenses, appeared to weigh more heavily on investor sentiment than the positive top-line performance.
Eyecare company Bausch + Lomb (NYSE:BLCO) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 5.1% year on year to $1.28 billion. The company’s full-year revenue guidance of $5.1 billion at the midpoint came in 1.4% above analysts’ estimates. Its non-GAAP profit of $0.07 per share was 16.9% below analysts’ consensus estimates.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2025 financial results.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Ophthalmology and Therapy has published results from a phase 3 study which assessed the efficacy and safety of LUMIFY Preservative Free redness reliever eye drops compared to LUMIFY redness reliever eye drops for reducing ocular redness.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Bausch + Lomb (NYSE:BLCO) and its peers.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today launched “Eyes Tell the Story: The Impact of Dry Eye.” The campaign aims to educate about dry eye through personal stories, compelling imagery and new survey data, and encourages people with symptoms to speak with their eye doctor to find relief.
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 30, 2025. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call.
NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Bausch + Lomb Corporation (“Bausch & Lomb” or the “Company”) (NYSE:BLCO) on behalf of Bausch & Lomb stockholders. Our investigation concerns whether Bausch & Lomb has violated the federal securities laws and/or engaged in other unlawful business practices.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the “Issuers”), have closed the upsized offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 (the “Notes”). In addition, the company announced that it has completed a partial refinancing of its credit agreement, and in connection with such refinancing, it has entered into a third amendment (the “Third Amendment”) to its existing credit agreement providing for a $2.325 billion term B loan facility maturing in 2031 (the “New Term B Loans”) and an $800 million revolving credit facility maturing in 2030 (subject to customary “springing” maturity provisions) (the “New Revolving Credit Facility”).
The Law Offices of Frank R. Cruz continues its investigation of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Law Offices of Howard G. Smith continues its investigation on behalf of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) investors concerning the Company’s possible violations of federal securities laws.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) investors concerning the Company’s possible violations of the federal securities laws.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the “Issuers”), have priced the offering of €675 million aggregate principal amount of senior secured floating rate notes due 2031 (“Notes”). The size of the offering was increased from the previously announced €600 million aggregate principal amount of Notes. The Notes will be sold to investors at a price of 99.500% of the principal amount thereof.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live better, today announced that its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb Incorporated (collectively, the “Issuers”), have launched an offering of €600 million aggregate principal amount of senior secured floating rate notes (“Notes”).
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Bausch + Lomb Corporation (“Bausch + Lomb” or “the Company”) (NYSE: BLCO) for violations of the securities laws.
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation (“Bausch + Lomb” or the “Company”) (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
